Skip to main content
. 2026 Oct 29;17:1947706. doi: 10.3389/fpsyt.2026.1947706

Table 7.

Univariable and multivariable logistic regression analyses of factors associated with clinical outcomes.

Variable Univariable OR (95% CI) p Multivariable aOR (95% CI) p
Outcome 1: CGI-I score of 1–2 at last recorded follow-up (550/650)
Age 4–10 years Reference Reference
Age 11–14 years 0.36 (0.16–0.81) 0.013 0.37 (0.17–0.83) 0.016
Age 15–17 years 0.25 (0.11–0.53) <0.001 0.28 (0.13–0.61) 0.001
Female sex 0.86 (0.55–1.33) 0.497 –
Prior antidepressant trial 0.39 (0.23–0.65) <0.001 0.46 (0.27–0.78) 0.004
Off-label prescribing 0.99 (0.60–1.61) 0.954 –
Any adverse effect 1.03 (0.61–1.73) 0.919 –
CGI-S moderately ill (vs mildly) 1.32 (0.52–3.36) 0.561 –
CGI-S markedly ill (vs mildly) 1.88 (0.70–5.08) 0.213 –
Major depressive disorder 0.94 (0.61–1.46) 0.796 –
Generalised anxiety disorder 1.23 (0.75–2.04) 0.415 –
ADHD 0.75 (0.48–1.18) 0.210 –
Psychiatric comorbidity 0.68 (0.41–1.13) 0.139 –
Concomitant treatment‖ 0.01 (0.00–0.04) <0.001 –
Outcome 2: Off-label prescribing (486/650)
Age 4–10 years Reference –
Age 11–14 years 0.72 (0.43–1.21) 0.220 –
Age 15–17 years 0.66 (0.40–1.09) 0.105 –
Female sex 0.78 (0.54–1.12) 0.177 –
Prior antidepressant trial 1.17 (0.69–2.00) 0.561 –
CGI-I score of 1–2 0.99 (0.60–1.61) 0.954 –
Psychiatric comorbidity 0.99 (0.67–1.47) 0.972 –
ADHD 1.68 (1.10–2.55) 0.016 1.46 (0.94–2.28) 0.096
Generalised anxiety disorder 4.01 (2.34–6.86) <0.001 2.41 (1.35–4.30) 0.003
Major depressive disorder 0.23 (0.16–0.33) <0.001 0.31 (0.21–0.47) <0.001
Outcome 3: Any adverse effect (139/650)
Age 4–10 years Reference Reference
Age 11–14 years 1.25 (0.72–2.17) 0.427 0.90 (0.50–1.62) 0.728
Age 15–17 years 1.56 (0.92–2.63) 0.099 0.87 (0.48–1.57) 0.644
Female sex 0.77 (0.53–1.13) 0.180 –
Prior antidepressant trial 2.29 (1.41–3.71) <0.001 1.69 (1.00–2.86) 0.051
Concomitant treatment 3.80 (2.54–5.69) <0.001 3.32 (2.14–5.16) <0.001
Major depressive disorder 1.14 (0.78–1.67) 0.503 –
Generalised anxiety disorder 0.49 (0.30–0.79) 0.004 0.58 (0.35–0.97) 0.038
ADHD 1.96 (1.32–2.90) <0.001 1.77 (1.17–2.69) 0.007
Off-label prescribing 1.16 (0.75–1.81) 0.499 –

Variables with p < 0.10 in univariable analysis were entered into the multivariable models. Outcome 1 model: age group and prior antidepressant trial (likelihood-ratio test for age group, p = 0.002; Hosmer–Lemeshow p = 0.608; AUC 0.64). Outcome 2 model: ADHD, GAD and MDD (Hosmer–Lemeshow p = 0.523; AUC 0.71). Outcome 3 model: age group, prior antidepressant trial, concomitant treatment, GAD and ADHD (Hosmer–Lemeshow p = 0.005; AUC 0.71). ‖Not entered into the multivariable model because concomitant agents were frequently added in response to partial improvement (reverse causation). Associations are exploratory and should not be interpreted causally. ADHD, attention-deficit/hyperactivity disorder; aOR, adjusted odds ratio; AUC, area under the receiver operating characteristic curve; CGI-I/S, Clinical Global Impression–Improvement/Severity; CI, confidence interval; GAD, generalised anxiety disorder; MDD, major depressive disorder; OR, odds ratio. p values < 0.05 are statistically significant.